GERN
Geron Corporation
$1.51
-0.06
(-3.82%)
Mkt Cap
968.70M
Volume
8,300,496
52W Range
1.04-2.01
Sector
Healthcare
Beta
0.60
EPS (TTM)
-0.10 USD
P/E Ratio
-10.15
Revenue (TTM)
204.56M USD
Rev Growth (5Y)
+273.6%
EPS Growth (5Y)
N/A
Company Description
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 183.88M | 76.99M | 237,000 | 596,000 | 1.39M | 253,000 | 460,000 | 1.07M | 1.06M | 6.16M | 36.37M | 1.15M |
| Net Income | (85.78M) | (174.57M) | (184.13M) | (141.90M) | (116.11M) | (75.62M) | (68.55M) | (27.02M) | (27.92M) | (29.54M) | 46,000 | (35.67M) |
| EPS | -0.13 | -0.27 | -0.32 | -0.37 | -0.37 | -0.28 | -0.33 | -0.15 | -0.18 | -0.19 | 0.00 | -0.23 |
| Free Cash Flow | (111.09M) | (219.30M) | (168.57M) | (127.81M) | (95.76M) | (67.05M) | (44.24M) | (21.02M) | (20.56M) | (18.43M) | (24.29M) | 9.22M |
| FCF / Share | -0.17 | -0.34 | -0.30 | -0.34 | -0.29 | -0.25 | -0.23 | -0.12 | -0.13 | -0.12 | -0.15 | 0.06 |
| Operating CF | (111.04M) | (218.62M) | (167.74M) | (127.38M) | (95.56M) | (66.65M) | (43.83M) | (21.01M) | (20.56M) | (18.37M) | (24.20M) | 9.35M |
| Total Assets | 570.54M | 593.78M | 394.08M | 190.57M | 226.03M | 270.73M | 165.52M | 185.28M | 110.31M | 130.25M | 148.76M | 172.51M |
| Total Debt | 251.57M | 121.72M | 85.90M | 55.75M | 55.00M | 29.72M | 2.55M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 79.44M | 79.02M | 70.02M | 56.84M | 34.87M | 9.93M | 13.64M | 10.84M | 16.60M | 13.08M | 21.52M | 43.06M |
| Book Value | 225.87M | 280.32M | 247.95M | 80.00M | 126.42M | 210.95M | 135.16M | 177.73M | 103.80M | 122.38M | 142.13M | 130.71M |
| Return on Equity | -0.38 | -0.62 | -0.74 | -1.77 | -0.92 | -0.36 | -0.51 | -0.15 | -0.27 | -0.24 | 0.00 | -0.27 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 57.48M | 51.84M | 48.02M | 47.23M | 49.04M | 39.60M | 47.54M | 28.27M | 882,000 | 304,000 | 23,000 | 164,000 |
| Net Income | (16.68M) | (3.64M) | (31.14M) | (18.43M) | (16.38M) | (19.84M) | (25.35M) | (26.45M) | (67.38M) | (55.39M) | (51.97M) | (44.80M) |
| EPS | -0.02 | -0.01 | -0.05 | -0.03 | -0.02 | -0.03 | -0.04 | -0.04 | -0.10 | -0.09 | -0.09 | -0.08 |
| Free Cash Flow | (16.05M) | (63.16M) | (22.10M) | (13.49M) | (27.55M) | (47.98M) | (43.80M) | (58.94M) | (53.68M) | (62.87M) | (41.00M) | (51.03M) |
| FCF / Share | -0.02 | -0.09 | -0.03 | -0.02 | -0.04 | -0.07 | -0.07 | -0.09 | -0.08 | -0.10 | -0.07 | -0.09 |
| Operating CF | (15.83M) | (62.91M) | (22.07M) | (13.58M) | (27.41M) | (47.98M) | (43.95M) | (58.94M) | (53.48M) | (62.25M) | (40.94M) | (50.84M) |
| Total Assets | 519.01M | 534.12M | 570.54M | 567.38M | 555.20M | 562.45M | 593.78M | 444.95M | 449.40M | 482.07M | 394.08M | 413.02M |
| Total Debt | 122.14M | 251.84M | 251.57M | 121.92M | 121.84M | 121.78M | 121.72M | 87.26M | 87.04M | 86.53M | 85.90M | 56.02M |
| Cash & Equiv | 62.64M | 70.78M | 79.44M | 78.12M | 77.73M | 83.75M | 79.02M | 60.34M | 116.94M | 189.76M | 71.14M | 30.71M |
| Book Value | 218.61M | 229.11M | 225.87M | 248.71M | 259.53M | 268.24M | 280.32M | 292.28M | 306.69M | 344.87M | 247.95M | 290.61M |
| Return on Equity | -0.08 | -0.02 | -0.14 | -0.07 | -0.06 | -0.07 | -0.09 | -0.09 | -0.22 | -0.16 | -0.21 | -0.15 |
GERN News
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Did Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Kuehn Law Encourages Investors of Geron Corporation to Contact Law Firm
Geron to Present at Upcoming Investor Conferences
ADAR1 Capital Management LLC Invests $647,000 in Geron Corporation $GERN
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corp: Management's Plan Taking Shape As Competition Heats Up In Myelofibrosis
Geron (NASDAQ:GERN) and Shattuck Labs (NASDAQ:STTK) Head to Head Comparison
Geron Corporation (GERN) Q2 2026 Earnings Call Transcript
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates